Cambrex, leading contract development and manufacturing organization (CDMO) that provides drug substance development and manufacturing, has announced that one of its companies, Snapdragon Chemistry, a specialist in active pharmaceutical ingredient (API) batch and continuous flow process development, has successfully developed a new liquid-phase peptide synthesis (LPPS) technology.
The technology, according to a press release, “utilizes traditional active pharmaceutical ingredient (API) batch reactors and continuous flow, obviating the dependency on specialized, solid-phase reactors,” thus limiting demand for solvents and the need for excess reagents when compared to standard solid-state peptide synthesis processes.
“Over the past several years, we have made significant investments in the research and development of complex synthetics, specifically to reduce the economic and environmental impacts of manufacturing peptides and oligonucleotides,” said Dr. Matt Bio, Chief Scientific Officer, Cambrex, of the company’s continued commitment to investing in research and development.
The new technology can support peptides up to 12 residues long, with larger peptides assembled in liquid phase using a convergent fragment coupling approach, processes that can be scaled the same way they would if traditional small molecules were used. The company’s efforts are accompanied by the development of unique capabilities in peptide and protein crystallization, including a screening platform that is used specifically for the discovery of crystalline forms of peptides and proteins. This facilitates improved product quality and reduces the need for time-consuming preparative processes like chromatography and lyophilization.
